|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:AGPAT5-FDFT1 (FusionGDB2 ID:HG55326TG2222) |
Fusion Gene Summary for AGPAT5-FDFT1 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: AGPAT5-FDFT1 | Fusion gene ID: hg55326tg2222 | Hgene | Tgene | Gene symbol | AGPAT5 | FDFT1 | Gene ID | 55326 | 2222 |
| Gene name | 1-acylglycerol-3-phosphate O-acyltransferase 5 | farnesyl-diphosphate farnesyltransferase 1 | |
| Synonyms | 1AGPAT5|LPAATE | DGPT|ERG9|SQS|SQSD|SS | |
| Cytomap | ('AGPAT5')('FDFT1') 8p23.1 | 8p23.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | 1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon1-AGP acyltransferase 51-AGPAT 51-acylglycerol-3-phosphate O-acyltransferase 5 (lysophosphatidic acid acyltransferase, epsilon)lysophosphatidic acid acyltransferase epsilontesticular tissue protei | squalene synthaseFPP:FPP farnesyltransferasepresqualene-di-diphosphate synthasesqualene synthetase | |
| Modification date | 20200313 | 20200320 | |
| UniProtAcc | Q9NUQ2 | P37268 | |
| Ensembl transtripts involved in fusion gene | ENST00000285518, ENST00000530716, | ||
| Fusion gene scores | * DoF score | 9 X 7 X 6=378 | 12 X 9 X 5=540 |
| # samples | 9 | 11 | |
| ** MAII score | log2(9/378*10)=-2.0703893278914 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(11/540*10)=-2.29545588352617 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: AGPAT5 [Title/Abstract] AND FDFT1 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | AGPAT5(6590171)-FDFT1(11689027), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | AGPAT5-FDFT1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. AGPAT5-FDFT1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Fusion gene breakpoints across AGPAT5 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across FDFT1 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | STAD | TCGA-BR-8372-01A | AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689027 | + |
Top |
Fusion Gene ORF analysis for AGPAT5-FDFT1 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5CDS-3UTR | ENST00000285518 | ENST00000443614 | AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689027 | + |
| 5CDS-3UTR | ENST00000285518 | ENST00000446331 | AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689027 | + |
| 5CDS-3UTR | ENST00000285518 | ENST00000525777 | AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689027 | + |
| 5CDS-3UTR | ENST00000285518 | ENST00000525900 | AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689027 | + |
| 5CDS-3UTR | ENST00000285518 | ENST00000528643 | AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689027 | + |
| 5CDS-3UTR | ENST00000285518 | ENST00000528812 | AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689027 | + |
| 5CDS-3UTR | ENST00000285518 | ENST00000530664 | AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689027 | + |
| In-frame | ENST00000285518 | ENST00000220584 | AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689027 | + |
| In-frame | ENST00000285518 | ENST00000538689 | AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689027 | + |
| intron-3CDS | ENST00000530716 | ENST00000220584 | AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689027 | + |
| intron-3CDS | ENST00000530716 | ENST00000538689 | AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689027 | + |
| intron-3UTR | ENST00000530716 | ENST00000443614 | AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689027 | + |
| intron-3UTR | ENST00000530716 | ENST00000446331 | AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689027 | + |
| intron-3UTR | ENST00000530716 | ENST00000525777 | AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689027 | + |
| intron-3UTR | ENST00000530716 | ENST00000525900 | AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689027 | + |
| intron-3UTR | ENST00000530716 | ENST00000528643 | AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689027 | + |
| intron-3UTR | ENST00000530716 | ENST00000528812 | AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689027 | + |
| intron-3UTR | ENST00000530716 | ENST00000530664 | AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689027 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000285518 | AGPAT5 | chr8 | 6590171 | + | ENST00000538689 | FDFT1 | chr8 | 11689027 | + | 1540 | 807 | 231 | 1181 | 316 |
| ENST00000285518 | AGPAT5 | chr8 | 6590171 | + | ENST00000220584 | FDFT1 | chr8 | 11689027 | + | 1882 | 807 | 231 | 1181 | 316 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000285518 | ENST00000538689 | AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689027 | + | 0.002313243 | 0.99768674 |
| ENST00000285518 | ENST00000220584 | AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689027 | + | 0.001298608 | 0.99870133 |
Top |
Fusion Genomic Features for AGPAT5-FDFT1 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689026 | + | 2.58E-12 | 1 |
| AGPAT5 | chr8 | 6590171 | + | FDFT1 | chr8 | 11689026 | + | 2.58E-12 | 1 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
 |
Top |
Fusion Protein Features for AGPAT5-FDFT1 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr8:6590171/chr8:11689027) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| AGPAT5 | FDFT1 |
| FUNCTION: Converts 1-acyl-sn-glycerol-3-phosphate (lysophosphatidic acid or LPA) into 1,2-diacyl-sn-glycerol-3-phosphate (phosphatidic acid or PA) by incorporating an acyl moiety at the sn-2 position of the glycerol backbone (PubMed:21173190). Acts on LPA containing saturated or unsaturated fatty acids C15:0-C20:4 at the sn-1 position using C18:1-CoA as the acyl donor (PubMed:21173190). Also acts on lysophosphatidylethanolamine using oleoyl-CoA, but not arachidonoyl-CoA, and lysophosphatidylinositol using arachidonoyl-CoA, but not oleoyl-CoA (PubMed:21173190). Activity toward lysophosphatidylglycerol not detectable (PubMed:21173190). {ECO:0000269|PubMed:21173190}. | FUNCTION: Catalyzes the condensation of 2 farnesyl pyrophosphate (FPP) moieties to form squalene. Proceeds in two distinct steps. In the first half-reaction, two molecules of FPP react to form the stable presqualene diphosphate intermediate (PSQPP), with concomitant release of a proton and a molecule of inorganic diphosphate. In the second half-reaction, PSQPP undergoes heterolysis, isomerization, and reduction with NADPH or NADH to form squalene. It is the first committed enzyme of the sterol biosynthesis pathway. {ECO:0000269|PubMed:10896663, ECO:0000269|PubMed:24531458}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | AGPAT5 | chr8:6590171 | chr8:11689027 | ENST00000285518 | + | 4 | 8 | 93_98 | 165 | 365.0 | Motif | HXXXXD motif |
| Hgene | AGPAT5 | chr8:6590171 | chr8:11689027 | ENST00000285518 | + | 4 | 8 | 15_35 | 165 | 365.0 | Transmembrane | Helical |
| Hgene | AGPAT5 | chr8:6590171 | chr8:11689027 | ENST00000285518 | + | 4 | 8 | 61_81 | 165 | 365.0 | Transmembrane | Helical |
| Tgene | FDFT1 | chr8:6590171 | chr8:11689027 | ENST00000220584 | 5 | 8 | 384_404 | 293 | 418.0 | Transmembrane | Helical |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | AGPAT5 | chr8:6590171 | chr8:11689027 | ENST00000285518 | + | 4 | 8 | 344_364 | 165 | 365.0 | Transmembrane | Helical |
| Tgene | FDFT1 | chr8:6590171 | chr8:11689027 | ENST00000220584 | 5 | 8 | 284_304 | 293 | 418.0 | Transmembrane | Helical |
Top |
Fusion Gene Sequence for AGPAT5-FDFT1 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >2963_2963_1_AGPAT5-FDFT1_AGPAT5_chr8_6590171_ENST00000285518_FDFT1_chr8_11689027_ENST00000220584_length(transcript)=1882nt_BP=807nt CGGAGCCCCCTGCCCCGGCAGGGGGATGTGGCGATGGGTGAGGGTCATGGGGTGTGAGCATCCCTGAGCCATCGATCCGGGAGGGCCGCG GGTTCCCTTGCTTTGCCGCCGGGAGCGGCGCACGCAGCCCCGCACTCGCCTACCCGGCCCCGGGCGGCGGCGCGGCCCATGCGGCTGGGG GCGGAGGCTGGGAGCGGGTGGCGGGCGCGGCGGCCCGGGCCCGGGCGGTGATTGGCCGCCTGCTGGCCGCGACTGAGGCCCGGGAGGCGG GCGGGGAGCGCAGGCGGAGCTCGCTGCCGCCGAGCTGAGAAGATGCTGCTGTCCCTGGTGCTCCACACGTACTCCATGCGCTACCTGCTG CCCAGCGTCGTGCTCCTGGGCACGGCGCCCACCTACGTGTTGGCCTGGGGGGTCTGGCGGCTGCTCTCCGCCTTCCTGCCCGCCCGCTTC TACCAAGCGCTGGACGACCGGCTCTACTGCGTCTACCAGAGCATGGTGCTCTTCTTCTTCGAGAATTACACCGGGGTCCAGATATTGCTA TATGGAGATTTGCCAAAAAATAAAGAAAATATAATATATTTAGCAAATCATCAAAGCACAGTTGACTGGATTGTTGCTGACATCTTGGCC ATCAGGCAGAATGCGCTAGGACATGTGCGCTACGTGCTGAAAGAAGGGTTAAAATGGCTGCCATTGTATGGGTGTTACTTTGCTCAGCAT GGAGGAATCTATGTAAAGCGCAGTGCCAAATTTAACGAGAAAGAGATGCGAAACAAGTTGCAGAGCTACGTGGACGCAGGAACTCCAGTG ATGGCCATTGCCACTTTGGCTGCCTGTTATAATAACCAGCAGGTGTTCAAAGGGGCAGTGAAGATTCGGAAAGGGCAAGCAGTGACCCTG ATGATGGATGCCACCAATATGCCAGCTGTCAAAGCCATCATATATCAGTATATGGAAGAGATTTATCATAGAATCCCCGACTCAGACCCA TCTTCTAGCAAAACAAGGCAGATCATCTCCACCATCCGGACGCAGAATCTTCCCAACTGTCAGCTGATTTCCCGAAGCCACTACTCCCCC ATCTACCTGTCGTTTGTCATGCTTTTGGCTGCCCTGAGCTGGCAGTACCTGACCACTCTCTCCCAGGTAACAGAAGACTATGTTCAGACT GGAGAACACTGATCCCAAATTTGTCCATAGCTGAAGTCCACCATAAAGTGGATTTACTTTTTTTCTTTAAGGATGGATGTTGTGTTCTCT TTATTTTTTTCCTACTACTTTAATCCCTAAAAGAACGCTGTGTGGCTGGGACCTTTAGGAAAGTGAAATGCAGGTGAGAAGAACCTAAAC ATGAAAGGAAAGGGTGCCTCATCCCAGCAACCTGTCCTTGTGGGTGATGATCACTGTGCTGCTTGTGGCTCATGGCAGAGCATTCAGTGC CACGGTTTAGGTGAAGTCGCTGCATATGTGACTGTCATGAGATCCTACTTAGTATGATCCTGGCTAGAATGATAATTAAAAGTATTTAAT TTGAAGCACCATTTGAATGTTCGTAATAGTAGAAAATGATGTGAATTTTCTTTCTGTTCGGCTCCTATTTTTCTCATCATTTTGTTTTCT TTAATTGGGTTGAATGGAGTAGATAGAAATATTTATGGTTTAGGTAACAGTTAGATGTTTCCTAAGAATGCAAACTGCCTTTTCCACACA AAGGCTGGGAATAAAATTCTGGGTATTCTCGTATTCTCATTTAAAGGAGTTTAGCTTTCAGAGAGAAACAGCAGGATTGCTTTTGACCTT TTAGAAGATTGGTCTCCAGTAAAGGTGGACATTTTTGAGATTTTTATAATAAAGAATTTAATTGCTCTGCATTTGTCAAGTA >2963_2963_1_AGPAT5-FDFT1_AGPAT5_chr8_6590171_ENST00000285518_FDFT1_chr8_11689027_ENST00000220584_length(amino acids)=316AA_BP=192 MAACWPRLRPGRRAGSAGGARCRRAEKMLLSLVLHTYSMRYLLPSVVLLGTAPTYVLAWGVWRLLSAFLPARFYQALDDRLYCVYQSMVL FFFENYTGVQILLYGDLPKNKENIIYLANHQSTVDWIVADILAIRQNALGHVRYVLKEGLKWLPLYGCYFAQHGGIYVKRSAKFNEKEMR NKLQSYVDAGTPVMAIATLAACYNNQQVFKGAVKIRKGQAVTLMMDATNMPAVKAIIYQYMEEIYHRIPDSDPSSSKTRQIISTIRTQNL PNCQLISRSHYSPIYLSFVMLLAALSWQYLTTLSQVTEDYVQTGEH -------------------------------------------------------------- >2963_2963_2_AGPAT5-FDFT1_AGPAT5_chr8_6590171_ENST00000285518_FDFT1_chr8_11689027_ENST00000538689_length(transcript)=1540nt_BP=807nt CGGAGCCCCCTGCCCCGGCAGGGGGATGTGGCGATGGGTGAGGGTCATGGGGTGTGAGCATCCCTGAGCCATCGATCCGGGAGGGCCGCG GGTTCCCTTGCTTTGCCGCCGGGAGCGGCGCACGCAGCCCCGCACTCGCCTACCCGGCCCCGGGCGGCGGCGCGGCCCATGCGGCTGGGG GCGGAGGCTGGGAGCGGGTGGCGGGCGCGGCGGCCCGGGCCCGGGCGGTGATTGGCCGCCTGCTGGCCGCGACTGAGGCCCGGGAGGCGG GCGGGGAGCGCAGGCGGAGCTCGCTGCCGCCGAGCTGAGAAGATGCTGCTGTCCCTGGTGCTCCACACGTACTCCATGCGCTACCTGCTG CCCAGCGTCGTGCTCCTGGGCACGGCGCCCACCTACGTGTTGGCCTGGGGGGTCTGGCGGCTGCTCTCCGCCTTCCTGCCCGCCCGCTTC TACCAAGCGCTGGACGACCGGCTCTACTGCGTCTACCAGAGCATGGTGCTCTTCTTCTTCGAGAATTACACCGGGGTCCAGATATTGCTA TATGGAGATTTGCCAAAAAATAAAGAAAATATAATATATTTAGCAAATCATCAAAGCACAGTTGACTGGATTGTTGCTGACATCTTGGCC ATCAGGCAGAATGCGCTAGGACATGTGCGCTACGTGCTGAAAGAAGGGTTAAAATGGCTGCCATTGTATGGGTGTTACTTTGCTCAGCAT GGAGGAATCTATGTAAAGCGCAGTGCCAAATTTAACGAGAAAGAGATGCGAAACAAGTTGCAGAGCTACGTGGACGCAGGAACTCCAGTG ATGGCCATTGCCACTTTGGCTGCCTGTTATAATAACCAGCAGGTGTTCAAAGGGGCAGTGAAGATTCGGAAAGGGCAAGCAGTGACCCTG ATGATGGATGCCACCAATATGCCAGCTGTCAAAGCCATCATATATCAGTATATGGAAGAGATTTATCATAGAATCCCCGACTCAGACCCA TCTTCTAGCAAAACAAGGCAGATCATCTCCACCATCCGGACGCAGAATCTTCCCAACTGTCAGCTGATTTCCCGAAGCCACTACTCCCCC ATCTACCTGTCGTTTGTCATGCTTTTGGCTGCCCTGAGCTGGCAGTACCTGACCACTCTCTCCCAGGTAACAGAAGACTATGTTCAGACT GGAGAACACTGATCCCAAATTTGTCCATAGCTGAAGTCCACCATAAAGTGGATTTACTTTTTTTCTTTAAGGATGGATGTTGTGTTCTCT TTATTTTTTTCCTACTACTTTAATCCCTAAAAGAACGCTGTGTGGCTGGGACCTTTAGGAAAGTGAAATGCAGGTGAGAAGAACCTAAAC ATGAAAGGAAAGGGTGCCTCATCCCAGCAACCTGTCCTTGTGGGTGATGATCACTGTGCTGCTTGTGGCTCATGGCAGAGCATTCAGTGC CACGGTTTAGGTGAAGTCGCTGCATATGTGACTGTCATGAGATCCTACTTAGTATGATCCTGGCTAGAATGATAATTAAAAGTATTTAAT TTGAAGCACC >2963_2963_2_AGPAT5-FDFT1_AGPAT5_chr8_6590171_ENST00000285518_FDFT1_chr8_11689027_ENST00000538689_length(amino acids)=316AA_BP=192 MAACWPRLRPGRRAGSAGGARCRRAEKMLLSLVLHTYSMRYLLPSVVLLGTAPTYVLAWGVWRLLSAFLPARFYQALDDRLYCVYQSMVL FFFENYTGVQILLYGDLPKNKENIIYLANHQSTVDWIVADILAIRQNALGHVRYVLKEGLKWLPLYGCYFAQHGGIYVKRSAKFNEKEMR NKLQSYVDAGTPVMAIATLAACYNNQQVFKGAVKIRKGQAVTLMMDATNMPAVKAIIYQYMEEIYHRIPDSDPSSSKTRQIISTIRTQNL PNCQLISRSHYSPIYLSFVMLLAALSWQYLTTLSQVTEDYVQTGEH -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for AGPAT5-FDFT1 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for AGPAT5-FDFT1 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for AGPAT5-FDFT1 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Tgene | C0006868 | Cannabis Abuse | 1 | CTD_human | |
| Tgene | C0006870 | Cannabis Dependence | 1 | CTD_human | |
| Tgene | C0009171 | Cocaine Abuse | 1 | CTD_human | |
| Tgene | C0018614 | Hashish Abuse | 1 | CTD_human | |
| Tgene | C0024809 | Marijuana Abuse | 1 | CTD_human | |
| Tgene | C0031391 | Phencyclidine Abuse | 1 | CTD_human | |
| Tgene | C0036572 | Seizures | 1 | GENOMICS_ENGLAND | |
| Tgene | C0037268 | Skin Abnormalities | 1 | GENOMICS_ENGLAND | |
| Tgene | C0234398 | Visual Cortex Disorder | 1 | GENOMICS_ENGLAND | |
| Tgene | C0236735 | Cannabis-Related Disorder | 1 | CTD_human | |
| Tgene | C0236736 | Cocaine-Related Disorders | 1 | CTD_human | |
| Tgene | C0236742 | Phencyclidine-Related Disorders | 1 | CTD_human | |
| Tgene | C0600427 | Cocaine Dependence | 1 | CTD_human | |
| Tgene | C2239176 | Liver carcinoma | 1 | CTD_human | |
| Tgene | C3553450 | Profound global developmental delay | 1 | GENOMICS_ENGLAND | |
| Tgene | C3714756 | Intellectual Disability | 1 | GENOMICS_ENGLAND | |
| Tgene | C4022810 | Abnormality of nervous system morphology | 1 | GENOMICS_ENGLAND | |
| Tgene | C4025871 | Abnormality of the face | 1 | GENOMICS_ENGLAND | |
| Tgene | C4048268 | Cortical visual impairment | 1 | GENOMICS_ENGLAND |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies